Andere Sprachen Lucid Diagnostics Inc.

Aktien

A3C5EE

US54948X1090

LUCD

Verzögert Nasdaq Andere Börsenplätze 16:35:57 26.04.2024			% 5 Tage	% 1. Jan.
0,6799 ^USD	+1,46 %		-14,64 %	-51,78 %

27.03.	LUCID DIAGNOSTICS INC. : Bewertung von Cantor Fitzgerald zum Kaufen erhalten	ZM
26.03.	Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lucid Diagnostics : Corporate Presentation - March 2024	03.04.
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results	27.03.
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	21.03.
Lucid Diagnostics Inc. announced that it has received $18.16 million in funding	13.03.
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	19.02.
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	09.02.
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors	08.02.
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12.12.
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	12.12.
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Lucid Diagnostics Inc. Appoints Shaun M. O?Neil as President	13.11.
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023	01.11.
Lucid Diagnostics Inc. announced that it has received $5 million in funding	01.11.
Lucid Diagnostics : Private Placement - Form 8-K	18.10.23
Lucid Diagnostics Inc. announced that it expects to receive $5 million in funding	18.10.23
Lucid Diagnostics Inc. announced that it has received $5 million in funding	18.10.23
Lucid Diagnostics Inc. announced that it expects to receive $5 million in funding	17.10.23
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference	21.09.23
Lucid Diagnostics Inc. Releases Positive Data from First Prospective Clinical Utility Study of Esoguard®? Esophageal Precancer Detection	07.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lucid Diagnostics Inc.

Aktien

A3C5EE

US54948X1090

LUCD

Andere Sprachen

Filter